Comments
Cadila Healthcare Ltd (Zydus Cadila), and its subsidiary Zydus Pharmaceuticals (USA) Inc., a generic pharmaceutical company in the United States, on Tuesday, announced that they have finalised an agreement with Supernus Pharmaceuticals, Inc., to settle all outstanding patent litigation related to Trokendi XR® (topiramate) extended-release capsules.
Under the terms of the agreement, Supernus will grant Zydus licence to market the company's generic version of Trokendi XR® (topiramate) extended-release capsules beginning on January 1, 2023, or earlier under certain circumstances, according to a release here.
Other terms of the settlement were not disclosed.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.